Subscribe
Home
Issues
Online First
2023
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
2021 Year in Review - Biosimilars
2021 Year in Review - Biosimilars
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
Biosimilars
2021 Year in Review - Biosimilars
The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC.
Read More ›
Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom
Biosimilars
2021 Year in Review - Biosimilars
The results of a noninterventional, retrospective study showed that rituximab originator and the rituximab-abbs biosimilars yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs use resulting in cost-savings.
Read More ›
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer
Biosimilars
2021 Year in Review - Biosimilars
Findings from modeling studies support adjuvant continuation of pertuzumab plus trastuzumab for patients achieving pathologic complete response among patients with high-risk,
HER2
-positive early breast cancer.
Read More ›
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
Biosimilars
2021 Year in Review - Biosimilars
Real-world outcomes from a retrospective, single-center study suggested that pegfilgrastim or its biosimilar pegfilgrastim-cbqv does not increase febrile neutropenia or delayed engraftment risk in patients with lymphoma and CLL and may be safe to use after administration of chemotherapy.
Read More ›
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
Biosimilars
2021 Year in Review - Biosimilars
The results of a retrospective, single-center analysis demonstrated that same-day pegfilgrastim or pegfilgrastim-cbqv was safe and effective in patients with diffuse large B-cell lymphoma who received a rituximab plus miniCHOP chemotherapy regimen, with no significant increase in febrile neutropenia or delayed engraftment.
Read More ›
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
Biosimilars
2021 Year in Review - Biosimilars
Real-world evidence demonstrated that the characteristics of patients with metastatic colorectal cancer who received bevacizumab-awwb in the first year after product launch were similar regardless of prior bevacizumab use, and that bevacizumab-awwb was used in new and continuing patients.
Read More ›
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
Biosimilars
2021 Year in Review - Biosimilars
An observational study indicates that the Oncology Care Model led to reduced use of some high-cost supportive care medications, suggesting the potential for alternative payment models to drive value-based changes in cancer medication use.
Read More ›
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
Biosimilars
2021 Year in Review - Biosimilars
The findings of a simulation modeling analysis demonstrate that conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb provides significant cost-savings, which could be reallocated on a budget-neutral basis to provide expanded access to additional prophylaxis or to antineoplastic therapy in patients with diffuse large B-cell lymphoma.
Read More ›
Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers
Biosimilars
2021 Year in Review - Biosimilars
A pharmacokinetic study demonstrated bioequivalence between SB12 and the eculizumab reference products, along with comparable pharmacodynamics, safety, and immunogenicity.
Read More ›
Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell NHL
Biosimilars
2021 Year in Review - Biosimilars
The preliminary results of a phase 2 study indicate that the combination of rituximab biosimilar plus pegylated interferon α-2b was well-tolerated and yielded responses in newly diagnosed advanced indolent B-cell NHL.
Read More ›
Page 1 of 3
1
2
3
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2023
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION